Story Poster
Photo by © Anthony Gruppuso-USA TODAY Sports
Clemson Basketball

No. 25 Clemson heads to Chestnut Hill to take on Boston College

January 2, 2018
1,394

No. 25 CLEMSON (12-1, 1-0 ACC) vs. BOSTON COLLEGE (10-4, 1-1 ACC)

Date: Wednesday, Jan. 3

Tipoff: 7:04 p.m. ET

Arena: Conte Forum (8,606)

Radio: CTN (Don Munson-pbp; Terrence Oglesby-color)

TV: RSN (Tom Werme-pbp; Jason Capel-color)

  • Clemson is 15-7 all-time against Boston College; 3-6 on the road.
  • The Tigers have won five-straight in the series dating back to 2013-14.
  • This will mark the first game Clemson will play as a ranked team in the AP Poll since Jan. 23, 2010 (No. 17) against Duke.
  • Tigers improved to 71-29 overall in Nov./Dec. under Brad Brownell.
  • Clemson is one of only three teams in the country to have a perfect record over the last two Decembers (13-0), joining Purdue and West Virginia (per Chris Forman, Purdue).

Series History 
Clemson is 15-7 all-time against Boston College.
Streak: The Tigers have won five games in a row in the series.

Tiger Tracks

  • The Tigers entered the AP Top 25 poll (No. 25) for the first time since the 2009-10 season. Clemson is receiving 45 votes in the USA Today Coaches Poll. Clemson’s RPI checks in at 14th nationally.
  • With the win over NC State, head coach Brad Brownell moved into sole possession of the most wins over ACC teams in Clemson history (regular season and tournament) with 60.
  • Coach Brownell (136 victories at Clemson) is two wins shy of tying and three shy of passing Oliver Purnell for the third most wins at Clemson.
  • With four rebounds, Donte Grantham would become just the sixth player in Clemson history to amass 1,000 points, 500 rebounds and 200 assists in a career.
  • Elijah Thomas is one of only three players in the country currently averaging at least 11.0 points, 8.5 rebounds and 2.5 blocks per game, while shooting at least 60.0 percent.(Sports-Reference CBB).
 
×
subscribe Verify your student status
See Subscription Benefits
Trial only available to users who have never subscribed or participated in a previous trial.